In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer".

BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X

Rivaroxaban: doi.org/10.1056/NEJMoa1814630

Apixaban: doi.org/10.1056/NEJMoa1814468

Back us on Patreon! www.patreon.com/plenarysession